Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP)

Carcinoma of Unknown Primary (CUP) is a heterogeneous and metastatic disease where the primary site of origin is undetectable. Currently, chemotherapy is the only state-of-art treatment option for CUP patients. The molecular profiling of the tumour, particularly mutation detection, offers a new trea...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2021-07, Vol.11 (1), p.15112-15112, Article 15112
Main Authors: Es, Hamidreza Aboulkheyr, Mahdizadeh, Hamid, Asl, Amir Abbas Hedayati, Totonchi, Mehdi
Format: Article
Language:English
Subjects:
631/67
631/67/1680
631/67/68
631/67/69
Chemotherapy
Clinical trials
Copy number
Genomics
Humanities and Social Sciences
Metastases
multidisciplinary
Mutation
Non-small cell lung carcinoma
p53 Protein
Science
Science (multidisciplinary)
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Carcinoma of Unknown Primary (CUP) is a heterogeneous and metastatic disease where the primary site of origin is undetectable. Currently, chemotherapy is the only state-of-art treatment option for CUP patients. The molecular profiling of the tumour, particularly mutation detection, offers a new treatment approach for CUP in a personalized fashion using targeted agents. We analyzed the mutation and copy number alterations profile of 1709 CUP samples deposited in the AACR Project Genomics Evidence Neoplasia Information Exchange (GENIE) cohort and explored potentially druggable mutations. We identified 52 significant mutated genes (SMGs) among CUP samples, in which 13 (25%) of SMGs were potentially targetable with either drugs are approved for the know primary tumour or undergoing clinical trials. The most variants detected were TP53 (43%), KRAS (19.90%), KMT2D (12.60%), and CDKN2A (10.30%). Additionally, using pan-cancer analysis, we found similar variants of TERT promoter in CUP and NSCLC samples, suggesting that these mutations may serve as a diagnostic marker for identifying the primary tumour in CUP. Taken together, the mutation profiling analysis of the CUP tumours may open a new way of identifying druggable targets and consequently administrating appropriate treatment in a personalized manner.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-021-94678-4